Aciex Respiratory Therapeutics

Founded 2017

Overview

We develop market leading respiratory drugs, combining newly improved compounds with high performance respiratory inhalers to make transformational pulmonary therapies. Our products are cost effective to produce and efficient to distribute. Serves unmet asthmatic & pediatric populations in in US & ROW. Novel single-unit dose improves patient outcomes & overcomes problems of conventional treatments, including contamination, cross-use and loss.

Management Team

President

Tom Cavanagh

Founder of Aciex and President since inception. Responsible for strategic direction of company, fund raising, investor relations and overseeing resources for clinical development projects, intellectual property, product partnering activities, and finance and administration. More than 20 years experience raising money and managing companies. Aciex is the fourth start-up. MBA from Kellogg School of Management. BA from University of Binghamton.

Chief Scientific Officer

Shahin Sanjar

25 years pharma experience at GSK & Novartis. Proven track record leading successful research projects. Areas of expertise include respiratory diseases (asthma, COPD, cystic fibrosis, allergy, etc.). Significant contribution to development of brands such as Advair, Serevent, Flovent, Flonase, Xolair, etc. BS in Physiology/Medical Biology from University of St. Andrews and PhD in Pharmacology from University of London